BVXP.LSE Bioventix
- Market cap
- GBX 107M
- P/E
- 14.2x
- P/B
- 9.38x
- ROE
- 66.7%
- Dividend yield
- 7.32%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is BVXP.LSE undervalued?
Graham numberBVXP.LSE trades 143.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioventix fundamental analysis
No fundamental analysis for Bioventix yet.
Bioventix stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The c…
Full company profileBioventix financial statements
Bioventix annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 7.25M | 8.75M | 9.29M | 10.3M | 10.9M | 11.7M | 12.8M | 13.6M | 13.1M | 13.0M |
| Gross Profit | 6.75M | 8.18M | 8.41M | 9.36M | 9.98M | 10.9M | 11.9M | 12.7M | 11.9M | 11.8M |
| Operating Income | 5.71M | 6.90M | 7.03M | 7.96M | 8.09M | 9.27M | 10.0M | 10.6M | 9.90M | 9.73M |
| EBITDA | 5.75M | 6.96M | 7.10M | 8.11M | 8.22M | 9.42M | 10.2M | 10.7M | 10.2M | 9.79M |
| Net Income | 4.92M | 5.66M | 5.86M | 7.20M | 6.73M | 7.67M | 8.37M | 8.10M | 7.58M | 7.61M |
| EPS | 0.95 | 1.08 | 1.12 | 1.38 | 1.28 | 1.46 | 1.58 | 1.53 | 1.43 | 1.44 |
| Balance Sheet | ||||||||||
| Total Assets | 10.4M | 11.9M | 11.6M | 13.3M | 12.9M | 13.1M | 13.3M | 13.7M | 12.9M | 12.8M |
| Total Liabilities | 236K | 865K | 787K | 779K | 1.09M | 1.30M | 1.22M | 1.73M | 1.31M | 1.41M |
| Shareholders' Equity | 10.1M | 11.0M | 10.8M | 12.5M | 11.8M | 11.8M | 12.1M | 12.0M | 11.6M | 11.4M |
| Cash & Short-term Investments | 6.17M | 6.99M | 6.54M | 8.08M | 6.49M | 6.13M | 5.72M | 6.00M | 5.08M | 5.26M |
| Total Debt | - | - | - | - | - | - | - | - | - | 11.0K |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.96M | 5.92M | 5.88M | 7.72M | 6.37M | 7.56M | 7.90M | 8.34M | 7.03M | 8.09M |
| Capital Expenditure | 21.7K | 108K | 84.5K | 340K | 260K | 11.8K | 10.6K | 15.9K | 19.2K | 71.6K |
| Free Cash Flow | 3.94M | 5.81M | 5.79M | 7.38M | 6.11M | 7.55M | 7.89M | 8.33M | 7.01M | 8.02M |
| Ratios | ||||||||||
| ROE | 48.5% | 51.4% | 54.1% | 57.5% | 56.9% | 64.9% | 69.4% | 67.5% | 65.7% | 66.7% |
| ROA | 47.4% | 47.7% | 50.5% | 54.2% | 52.2% | 58.5% | 63.0% | 59.0% | 59.0% | 59.4% |
| Net Profit Margin | 67.9% | 64.7% | 63.1% | 69.8% | 61.6% | 65.5% | 65.3% | 59.5% | 57.8% | 58.7% |
| Debt to Equity | - | - | - | - | - | - | - | - | - | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bioventix dividends
- Dividend yield
- 7.32%
- Forward dividend
- 1.50 GBX
- Payout ratio
- 102.9%
- Ex-dividend date
- Apr 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | 7.84M | 1.48 | 102.9% |
| 2025 | GBP 8.19M | 1.55 | 108.0% |
| 2024 | GBP 8.25M | 1.56 | 101.9% |
| 2023 | GBP 8.44M | 1.60 | 100.8% |
| 2022 | GBP 7.92M | 1.51 | 103.2% |
| 2021 | GBP 7.71M | 1.47 | 114.5% |
| 2020 | GBP 6.50M | 1.25 | 90.3% |
| 2019 | GBP 6.22M | 1.19 | 106.1% |
| 2018 | GBP 4.93M | 0.94 | 87.1% |
| 2017 | GBP 3.37M | 0.65 | 68.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bioventix
- Insiders 7.71%
- Institutions 59.01%
- Public & others 33.29%
- Shares outstanding 5.22M
- Free float 4.15M
Bioventix company profile
- Company name
- Bioventix
- Ticker
- BVXP.LSE
- ISIN
- GB00B4QVDF07
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- June
- Address
- 7 Romans Business Park, Farnham, United Kingdom, GU9 7SX
- Phone
- 44 12 5272 8001
- Website
- bioventix.com
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environmental biomonitoring platform, which reduces the time between sampling and results. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Bioventix management
2- Mr. Peter John Harrison MACEO & Director · born 1958
- Mr. Bruce Edward Heath HiscockCFO & Director · born 1958